PROstate Cancer TReatment Optimization Via Analysis of Circulating Tumour DNA (PROTRACT)
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04015622 |
Recruitment Status :
Recruiting
First Posted : July 11, 2019
Last Update Posted : September 21, 2023
|
Sponsor:
British Columbia Cancer Agency
Information provided by (Responsible Party):
British Columbia Cancer Agency
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Recruiting |
---|---|
Estimated Primary Completion Date : | April 1, 2025 |
Estimated Study Completion Date : | December 1, 2025 |
Publications:
Khalaf D, Annala M, Finch DL, et al. Phase 2 randomized cross-over trial of abiraterone + prednisone (ABI+P) vs enzalutamide (ENZ) for patients (pts) with metastatic castration resistant prostate cancer (mCPRC): Results for 2nd-line therapy. J Clin Oncol [Internet] 2018;36(15_suppl):5015.